OptiBiotix Health Regulatory News (OPTI)

19 January 2016

OptiBiotix Health plc

("OptiBiotix" or "the Company")

Professor Tim Spector joins Scientific Advisory Group

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products to tackle obesity, high cholesterol and diabetes, announces that Professor Tim Spector, author of 'The Diet Myth', has agreed to join the Company's Scientific Advisory Group ("SAG"). The SAG was created in October 2014 to support the scientific and clinical development of the Company's compounds and brings together world renowned scientists with expertise in satiation, the human microbiome, and novel food ingredients.

Tim Spector is a Professor of Genetic Epidemiology at King's College London, Hon Consultant Physician at Guys and St Thomas's Hospital, London, and Director of the crowd funded British Gut project. He has published over 700 academic papers, leads the largest microbiome project in the UK, and is author of 'The Diet Myth: The Real Science Behind What We Eat'. The Diet Myth summarises scientific studies in an easy to read narrative into how gut bacteria affect our body weight and general health.

Tim's pioneering research into microbes, genetics and diet is regularly covered by radio, television and major national and international newspapers. Tim's research expertise in the microbiome creates opportunities to collaborate and additional insight into the role of the microbiome in health and disease.

Stephen O'Hara, OptiBiotix's Chief Executive Officer, commented: "I am delighted that Tim has agreed to join our Scientific Advisory Group. His research interests in the microbiome open up the potential for new collaborations and development opportunities. Tim's ability to communicate complex scientific data to a wider public, as exemplified by his book 'The Diet Myth', will bring an increased consumer focus to our Scientific Advisory Group."

For further information, please contact:

About OptiBiotix Health PLC - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.